HVA and 5HIAA CSF measurements and 5HTP trials in some patients with involuntary movements.
D006916:5-Hydroxytryptophan / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D002819:Chorea / Q000134:cerebrospinal fluid / Q000188:drug therapy; D004298:Dopamine / Q000378:metabolism*; D004422:Dystonia Musculorum Deformans / Q000134:cerebrospinal fluid / Q000188:drug therapy; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid*; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000378:metabolism*; D009207:Myoclonus / Q000134:cerebrospinal fluid / Q000188:drug therapy; D010648:Phenylacetates / Q000134:cerebrospinal fluid*; D012701:Serotonin / Q000378:metabolism*; D014103:Torticollis / Q000134:cerebrospinal fluid / Q000188:drug therapy; D014202:Tremor / Q000134:cerebrospinal fluid / Q000188:drug therapy
D010648:Phenylacetates; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D006916:5-Hydroxytryptophan; D004298:Dopamine; D006719:Homovanillic Acid